Dr. Marco V. Benavides Sánchez. Medmultilingua.com /
Alzheimer’s disease remains one of the most difficult neurodegenerative disorders to diagnose in its early stages. By the time clinical symptoms emerge—memory loss, disorientation, impaired judgment—the brain damage accumulated over years is already irreversible. In this context, the application of artificial intelligence (AI) to integrated sets of biological, genetic, and imaging biomarkers offers, for the first time, a realistic perspective for diagnostic prediction.
A systematic review recently published in Artificial Intelligence in Medicine (Catino et al., 2026) rigorously analyzes 27 studies published between 2010 and 2025 that used machine learning algorithms to integrate two or more types of biomarkers for the early detection of neurocognitive decline. Their findings point to both significant advances and methodological limitations that affect the clinical translation of these tools.
A Multimodal Approach to the Complexity of Alzheimer’s Disease
The biological substrate of Alzheimer’s disease is multifactorial: deposits of beta-amyloid and tau proteins, progressive cortical atrophy, alterations in cerebral glucose metabolism, and synaptic dysfunctions precede clinical manifestation by decades. No single biomarker captures this complexity. Therefore, the combination of structural magnetic resonance imaging, plasma biomarkers—such as levels of phosphorylated tau p-tau217—genetic data such as the APOE ε4 allele, neuropsychological assessments, and even retinal imaging provides a more accurate representation of the neurodegenerative state.
AI systems that combine multiple types of medical information—such as brain scans, blood biomarkers, genetics, and cognitive tests—are much better at identifying early signs of Alzheimer’s than systems that rely on only one type of data. These multimodal AI models can detect very subtle patterns across large, complex datasets that doctors cannot easily see, and their performance is measured using a metric called AUC (Area Under the Curve). Scores between 0.85 and 0.95 indicate very strong accuracy in distinguishing normal aging from mild cognitive impairment and Alzheimer’s disease, showing that integrating diverse biomarker sources significantly improves diagnostic power.
Think of AUC like judging how well you can tell two suitcases apart on an airport conveyor belt—one belonging to a healthy person and the other to someone with Alzheimer’s. If you only look at one clue, like the suitcase’s color, you’ll guess correctly sometimes but not consistently, just like a unimodal model. But if you pay attention to many clues at once—weight, tags, scratches, stickers—you become far better at identifying the right suitcase.
That’s what multimodal AI does: it combines many types of medical information to make much more accurate distinctions. An AUC between 0.85 and 0.95 means the AI is extremely good at telling the “suitcases” apart, getting it right most of the time and performing far better than chance.
The challenge of longitudinal prediction
However, the most clinically relevant task—predicting which patients with Mild Cognitive Impairment will progress to Alzheimer’s disease within 2 to 5 years—yielded more modest results. The best models achieved AUCs of between 0.75 and 0.85 on MCI-to-AD conversion tasks. Although statistically promising, these values are still below the threshold needed to support individual clinical decisions with sufficient diagnostic certainty.
This means that although many AI models seem to perform very well in controlled research settings, their usefulness in real medical practice is limited because most studies did not test the models on completely new groups of patients. Without this “external validation,” a model may simply learn the quirks of the specific dataset it was trained on and then fail when used with people from different backgrounds, hospitals, or health conditions.
The QUADAS‑2 evaluation (a structured quality check that reviewers apply to each study to see whether its methods are reliable or whether there are weaknesses that could distort the results) showed that many studies had methodological weaknesses—such as small sample sizes and inconsistent ways of collecting data—which increase the risk of bias and make the results less reliable. In short, the impressive accuracy reported in experiments may not hold up in real‑world clinical environments because the studies were not designed robustly enough to guarantee generalizability.
Toward Clinical Application: What’s Missing?
The authors identify several conditions necessary for multimodal AI to reach clinical maturity. First, multicenter studies with thousands of participants and long-term longitudinal follow-up are required to capture the true heterogeneity of the disease. Second, it is essential to develop standards for biomarker acquisition and interpretation that allow comparability between studies and centers.
Finally, the interpretability of the models—the ability to explain which variables drive each prediction—is an essential ethical and regulatory requirement for implementation in healthcare settings. The integration of less invasive and lower-cost biomarkers, such as peripheral blood tests or retinal imaging, could democratize access to these tools, which is particularly relevant in settings with limited diagnostic resources.
The study by Catino and colleagues reinforces the evidence that multimodal AI represents a promising—and technically mature—path to transforming the early detection of Alzheimer’s disease. However, the transition from promise to real clinical impact will depend on the methodological rigor with which the next generations of models are built.
Reference
Catino, F. et al. (2026). Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: A systematic review. Artificial Intelligence in Medicine, 103389. https://doi.org/10.1016/j.artmed.2026.103389
Recommended Hashtags
#Alzheimer’s #ArtificialIntelligence #Biomarkers #Neuroscience #DigitalHealth #EarlyDiagnosis #AIinMedicine #HealthyAging #Medmultilingua
© Medmultilingua 2026 — Science accessible to everyone, worldwide.
Leave a Reply